NR4A3
NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer, Lung cancer and 1 more.
Overview
Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes. Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation.
CIViC holds 1 clinical evidence item and 1 assertion across 3 variants. Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.97, genetic association 0.33, somatic mutation 0.98, animal model 0.34).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer, Lung cancer and 1 more.
- 1 · What it is
NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer, Lung cancer and 1 more.
- 2 · What goes wrong in cancer
Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner.
- 3 · How drugs use it
No product in this corpus aims at NR4A3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7982 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92570 (protein name, function text, keywords and locations (REST API)); CIViC gene NR4A3 (1 evidence items, 1 assertions, 3 variants; diseases: Acinic Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000119508 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.52, sarcoma 0.67, lung cancer 0.51, chondrosarcoma 0.54 (GraphQL API, CC0))
Biology
Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes. Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site. Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A. Location: Nucleus (UniProt). Locus 9q31.1 (HGNC).
- Sarcomas: Open Targets association 0.67 with sarcoma (MONDO_0005089)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Chondrosarcoma: Open Targets association 0.54 with chondrosarcoma (MONDO_0008977)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Acinic Cell Carcinoma.
Latest papers
topQuery for this target: (TITLE:"NR4A3" OR ABSTRACT:"NR4A3" OR TITLE:"nuclear receptor subfamily 4 group A member 3" OR ABSTRACT:"nuclear receptor subfamily 4 group A member 3" OR TITLE:"Nuclear receptor subfamily 4 group A member 3" OR ABSTRACT:"Nuclear receptor subfamily 4 group A member 3" OR TITLE:"NOR1" OR ABSTRACT:"NOR1" OR TITLE:"MINOR" OR ABSTRACT:"MINOR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NR4A3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetERCC6
Shares Lung cancer (all types), CIViC, Open Targets Platform, Colorectal cancer.
- TargetPOU5F1
Shares Lung cancer (all types), CIViC, Open Targets Platform, Colorectal cancer.
- TargetHEY1
Shares Chondrosarcoma, Sarcomas (soft tissue, bone, GIST), Open Targets Platform.
- TargetETV1
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), CIViC, Open Targets Platform.
- TargetCREB3L1
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Open Targets Platform.
- TargetCREB3L2
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Open Targets Platform.
- TargetPRKN
Shares Lung cancer (all types), CIViC, Open Targets Platform.
- TargetAXIN2
Shares Lung cancer (all types), CIViC, Open Targets Platform, Colorectal cancer.